Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2001 November; 85(11): 1753–1758.
PMCID: PMC2363986

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer


c-Raf is an essential component of the extracellular related kinase (ERK) signal transduction pathway. Immunohistochemical staining indicated that c-Raf was present in 49/53 ovarian adenocarcinomas investigated and high c-Raf expression correlated significantly with poor survival (P = 0.002). c-Raf protein was detected in 15 ovarian cancer cell lines. Antisense oligodeoxynucleotides (ODNs) (ISIS 5132 and ISIS 13650) reduced c-Raf protein levels and inhibited cell proliferation in vitro. Selectivity was demonstrated by the lack of effect of ISIS 5132 on A-Raf or ERK, while a random ODN produced only minor effects on growth and did not influence c-Raf expression. ISIS 5132 produced enhanced apoptosis and cells accumulated in S and G 2/M phases of the cell cycle. In vivo, ISIS 5132 inhibited growth of the s.c. SKOV-3 xenograft while a mismatch ODN had no effect. These data indicate that high levels of c-Raf expression may be important in ovarian cancer and use of antisense ODNs targeted to c-Raf could provide a strategy for the treatment of this disease. © 2001 Cancer Research Campaign

Keywords: Raf, antisense, ovarian, cancer, oligodeoxynucleotide

Full Text

The Full Text of this article is available as a PDF (94K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Avruch J, Zhang XF, Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci. 1994 Jul;19(7):279–283. [PubMed]
  • Cho-Chung YS. Antisense oligonucleotide inhibition of serine/threonine kinases: an innovative approach to cancer treatment. Pharmacol Ther. 1999 May-Jun;82(2-3):437–449. [PubMed]
  • Cowsert LM. In vitro and in vivo activity of antisense inhibitors of ras: potential for clinical development. Anticancer Drug Des. 1997 Jul;12(5):359–371. [PubMed]
  • Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR. The ins and outs of Raf kinases. Trends Biochem Sci. 1994 Nov;19(11):474–480. [PubMed]
  • Fan Z, Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol. 1998 Jan;10(1):67–73. [PubMed]
  • Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999 Jan 21;18(3):813–822. [PubMed]
  • Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC, Smyth JF. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 1988 Nov 1;48(21):6166–6172. [PubMed]
  • Lau QC, Brüsselbach S, Müller R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene. 1998 Apr 9;16(14):1899–1902. [PubMed]
  • Levack PA, Mullen P, Anderson TJ, Miller WR, Forrest AP. DNA analysis of breast tumour fine needle aspirates using flow cytometry. Br J Cancer. 1987 Nov;56(5):643–646. [PMC free article] [PubMed]
  • Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol. 1997 Feb;71(2):173–179. [PubMed]
  • Monia BP. First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anticancer Drug Des. 1997 Jul;12(5):327–339. [PubMed]
  • Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med. 1996 Jun;2(6):668–675. [PubMed]
  • Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H, Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15481–15484. [PubMed]
  • Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D, et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol. 1999 Nov;17(11):3586–3595. [PubMed]
  • O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res. 1999 Dec;5(12):3977–3982. [PubMed]
  • Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature. 1993 May 6;363(6424):83–85. [PubMed]
  • Stewart CJ, Owens OJ, Richmond JA, McNicol AM. Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int J Gynecol Pathol. 1992 Oct;11(4):266–272. [PubMed]
  • Storm SM, Brennscheidt U, Sithanandam G, Rapp UR. raf oncogenes in carcinogenesis. Crit Rev Oncog. 1990;2(1):1–8. [PubMed]
  • Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993 Jul 1;53(13):3103–3108. [PubMed]
  • Witters L, Kumar R, Mandal M, Bennett CF, Miraglia L, Lipton A. Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Res Treat. 1999 Jan;53(1):41–50. [PubMed]
  • Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res. 1999 Nov;5(11):3357–3363. [PubMed]
  • Zheng CF, Guan KL. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J Biol Chem. 1993 Nov 15;268(32):23933–23939. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK